🇺🇸 FDA
Pipeline program

VX15/2503

VX15/2503-N-101

Phase 1 small_molecule completed

Quick answer

VX15/2503 for Multiple Sclerosis is a Phase 1 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
VACCINEX, INC.
Indication
Multiple Sclerosis
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials